SCHEMBL13747372

SCHEMBL13747372

COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ncc(-c4c[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)O)[C@@H](C)OC)n4)cn3)cc2F)[nH]1)[C@@H](C)OC

nearest known ligand 0.54

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 0.54
CYP2C9 P11712 5/20 0.54
NR1I2 O75469 2/20 0.54
KCNH2 Q12809 2/20 0.54
ABCB11 O95342 1/20 0.54
OPRK1 P41145 1/20 0.54
CYP1A2 P05177 3/20 0.51
CYP2D6 P10635 2/20 0.51
PRCP P42785 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12175149 0.97 CYP3A4 (0.56) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL13758847 0.95 CYP3A4 (0.60) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL12175147 0.92 CYP3A4 (0.64) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL4560542 0.92 CYP3A4 (0.61) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL4560541 0.92 CYP3A4 (0.61) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL19334184 0.92 CYP3A4 (0.51) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL19578421 0.90 CYP3A4 (0.50) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL12175209 0.90 CYP3A4 (0.60) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL13148320 0.90 CYP3A4 (0.53) CYP3A4CYP2C9NR1I2KCNH2ABCB11
SCHEMBL13758828 0.88 KCNH2 (0.47) CYP3A4CYP2C9NR1I2KCNH2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009102325-A1 IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-20 WO disclosed
WO-2008021927-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-21 WO disclosed